Skip to main content
. 2016 Dec 23;6:39738. doi: 10.1038/srep39738

Figure 5. Treatment with Efavirenz, but not other NNRTIs, affects claudin-5 immunoreactivity and localization in brain microvessels.

Figure 5

Mice were treated with various NNRTIs or vehicle for 30 days as described in the Materials and Methods. Claudin-5 (green), ZO-1 (red), and occludin (red) were analyzed by immunostaining in isolated brain microvessels. Nuclei were stained with Draq5 (blue). Left and middle columns in A and B are staining for specific tight junction proteins. The right column in (A) is colocalization of claudin-5 with ZO-1 and the right column in (B) is colocalization of claudin-5 with occludin. Arrows indicate discontinuous, absence of claudin-5 immunoreactivity and lack of ZO-1 or Occludin colocalization. (C) Quantification of mean fluorescence index (MFI) signal for tight junction proteins analyzed in isolated microvessels. Data obtained from 3 mice per group, 5–7 microvessels per mice. *p < 0.05; ***p < 0.001. EFV: Efavirenz; ETR: Etravirine; RPV: Rilpivirine.